NanoViricides Inc. (NNVC)

[arvitar]

The bad news has already long been out. The question is how long it will take the market to fully reprice NNVC accordingly.


The bad news is that at the start, Seymour represented to investors that NNVC would have three candidates in Phase-3 before end of 2010.

Now it's six years beyond 2010, and NNVC doesn't even have a single preclinical candidate it can call its "lead".

NNVC hasn't even able to move a single candidate off the laboratory bench and through IND-enabling studies, after eleven years and tens of millions of dollars spent.

Something is fundamentally wrong with the technology, the management, or (more likely) both.